Ranbaxy's journey as a company to end after merger with Sun

Ranbaxy Laboratories will cease to exist as a company after completion of the $ 4 billion merger with Sun Pharmaceuticals, although its brands will be kept alive in over 100 markets.

"The Ranbaxy entity will be merged into Sun Pharma and Sun Pharma will be the surviving entity post-merger," a Sun Pharma spokesperson told PTI.

On Ranbaxy's brands, he said: "...Ranbaxy has branded generics in more than 100 markets. We plan to keep these brands alive in most markets...The brand Ranbaxy itself has a rich heritage and value. We would like to preserve that."

Sun Pharma said April 7 it would fully acquire Ranbaxy, which was incorporated in 1961 and went public in 1973. It will offer 0.8 share of Sun Pharma for each Ranbaxy share, representing an implied value of Rs 457 per Ranbaxy share.

After approval by regulators and shareholders, a record date will be set for the share swap, after which the Ranbaxy stock will not be traded on the exchanges.

According to Daiichi Sankyo of Japan, which holds a 63.41 per cent stake in Ranbaxy, the merger is expected to close by the end of 2014.

The Japanese firm expects to get approval from Indian securities exchanges by June end, while shareholder meetings of Sun Pharma and Ranbaxy are expected at the end of August.

Daiichi acquired the Ranbaxy stake in 2008 for about Rs 22,000 crore after the erstwhile promoters, brothers Malvinder and Shivinder Singh, decided to exit.

The Sun Pharma spokesperson also sought to allay fears of large-scale layoffs of Ranbaxy staff.

"The areas of overlap are relatively limited. As a result, integrating sales and marketing across the companies should be possible," the official said.

After closure of the deal, the combined entity will become the largest pharmaceutical company in India, with an estimated combined revenue of $ 4.2 billion, and the fifth-largest speciality generics company in the world.

The entity will have operations in 65 countries, 47 manufacturing plants across five continents, and a significant platform of speciality and generic products marketed globally, including 629 abbreviated new drug applications.

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Copy the characters (respecting upper/lower case) from the image.

EDITORIAL OF THE DAY

  • India needs to think quick and act fast to crank up its crude reserves

    With China overtaking the US in crude oil imports in April with imports at 7.4 million barrels per day, its thirst for building reserves and proving i

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

Sarthak Raychaudhuri

vice-president, HR, Asia South Whirlpool of India

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

TODAY'S COLUMNS

Arun Kumar Jain

Politics has to be about problem solving

One of the most common sights every morning at major ...

Kuruvilla Pandikattu SJ

Start meditating to preserve grey matter

Since 1970, life expectancy around the world has risen dramatically, ...

Gautam Gupta

It’s ethnic wear all the way in Indian fashion

India is one of the most diverse countries in the ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture